Program
eculizumab
Also written as “Eculizumab”, “Eculizumab Injection” and “Soliris (eculizumab)”.
Its studies are mostly in Hemoglobinuria, Paroxysmal · Atypical Hemolytic Uremic Syndrome · Myasthenia Gravis · Neuromyelitis Optica · Guillain-Barre Syndrome, led by 4 companies.
Drug pageEculizumab: every studyAll 81 studies of it, academic ones too, with its approvals, label and forms.Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| AstraZenecaits history only | 311 open or running | phase 4since Mar 23, 2009 | Jul 18, 2005 | Dec 7, 2026phase 3 · NCT06724809 |
| AO GENERIUM | 20 open or running | phase 3since Jul 3, 2020 | Jul 3, 2020 | none ahead |
| Samsung Bioepisits history only | 20 open or running | phase 3since Aug 12, 2019 | Oct 24, 2018 | none ahead |
| Biocadits history only | 10 open or running | phase 3since May 16, 2025 | May 16, 2025 | none ahead |
Also a collaborator on its studies: CMIC Co, Ltd. Japan.
How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.
History and studies of AO GENERIUM only; the figures above count every company.
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
- Jul 3, 2020First study: phase 3 study in Hemoglobinuria, ParoxysmalFirst studyNCT04463056 · 32 enrolled · Russian Federation
- Nov 30, 2020Phase 3 study in Hemoglobinuria, ParoxysmalNCT04679103 · 50 enrolled · Russian Federation
TargetBeta
“Complement C5 inhibitor”ChEMBL 37, by rule
Other programs on C5
| Program | Company | Furthest phase | Studies |
|---|---|---|---|
| ravulizumabrule | AstraZeneca | phase 4 | 35 |
| pozelimabrule | Regeneron Pharmaceuticals | phase 4 | 14 |
| zilucoplanrule | UCB | phase 3 | 14 |
| vilobelimabrule | inflarx-gmbh | phase 3 | 13 |
| Crovalimabrule | Hoffmann-La Roche | phase 3 | 10 |
| cemdisiranrule | Regeneron Pharmaceuticals | phase 3 | 10 |
| ABBV-6628 | AbbVie | phase 2 | 1 |
Studies
All 2 AO GENERIUM leads, newest first. Each opens its study page.
| Study | Phase | Status | Primary completion | Size |
|---|---|---|---|---|
| NCT04679103Hemoglobinuria, Paroxysmal · Russian Federation | 3 | Completed | Apr 20, 2020 | 50 |
| NCT04463056Hemoglobinuria, Paroxysmal · Russian Federation | 3 | Completed | Oct 16, 2018 | 32 |
How it is read
Names in the registry
- “Eculizumab”, 23 entries
- “eculizumab”, 10 entries
- “Eculizumab Injection”, 1 entry
- “Soliris (eculizumab)”, 1 entry
- “Elizaria®”, 1 entry
Conditions, from the studies’ own filings
- Hemoglobinuria, Paroxysmal, 14 studies
- Atypical Hemolytic Uremic Syndrome, 7 studies
- Myasthenia Gravis, 5 studies
- Neuromyelitis Optica, 4 studies
- Guillain-Barre Syndrome, 1 study
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.